Tresperimus (Laboratoires Fournier)

Tresperimus (LF-08-0299) is an immunosuppressant under development by Laboratoires Fournier for its potential use in organ transplant rejection. Fournier has commenced phase III trials in the US and Europe [304203]. Tresperimus began phase I/II trials in 1995 for graft versus host rejection in combination with cyclosporine and tacrolimus, but later as first-line therapy. It demonstrated efficient immunosuppressive activity in a rat model of cardiac rejection [182951]. The company is seeking licensees for the product